Onconic Therapeutics to Earn from Jacuvo and Grow Anticancer and Obesity New Drugs [Why Bio]
Predicted impact: Low
Royalty and pipeline commentary; no new quantified deal.
Onconic Therapeutics온코닉테라퓨틱스
476060 · KOSDAQ · ₩476060 · 온코닉테라퓨틱스
₩13,070▲ ₩300 (2.35%)End-of-day · Oct 28, 2026 · End-of-day prices.
Onconic Therapeutics: "Zaqbo oral disintegrating tablet confirmed to show drug exposure equivalent to existing tablet"
Predicted impact: Low
Routine shareholders' meeting notice and proxy documents; procedural only.
Oncocross Therapeutics to expand anticancer and obesity drug development based on Jacuzbo royalties
Predicted impact: Low
Routine shareholder meeting notices already reported.
Oncocross Therapeutics: "Zaqubo has minimal drug interaction when combined with hyperlipidemia drugs"
Predicted impact: Low
Shareholder meeting notices already issued in the last 14 days.
Also known as: Onconic Therapeutics / 온코닉테라퓨틱스 / 476060 / KRX:476060
Source: KRX statistical information